The drugs show pharma at its best and its worst ... A drug for low libido, or 'acquired, generalised hypoactive sexual desire disorder' (HSDD) in premenopausal women, Addyi was approved in ...

This contributes to low diagnosis of HSDD in these countries. Presence of strong pipeline products which present in late phases of clinical trials are expected to get approved for commercialization in ...

The company’s lead product, the testosterone TEPI patch for HSDD in postmenopausal women ... support transdermal delivery of lower-potency drugs, in addition to reducing the size and thickness ...